420 related articles for article (PubMed ID: 36931725)
1. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.
Yan D; Yan B
Fundam Clin Pharmacol; 2023 Aug; 37(4):726-738. PubMed ID: 36931725
[TBL] [Abstract][Full Text] [Related]
2. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.
Hau RK; Wright SH; Cherrington NJ
Clin Transl Sci; 2022 Jul; 15(7):1599-1605. PubMed ID: 35505633
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
Jeong JH; Chokkakula S; Min SC; Kim BK; Choi WS; Oh S; Yun YS; Kang DH; Lee OJ; Kim EG; Choi JH; Lee JY; Choi YK; Baek YH; Song MS
Antiviral Res; 2022 Dec; 208():105430. PubMed ID: 36209984
[TBL] [Abstract][Full Text] [Related]
4. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
Atmar RL; Finch N
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
[TBL] [Abstract][Full Text] [Related]
5. The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion.
Chen TH; Tsai MJ; Chang CS; Xu L; Fu YS; Weng CF
J Infect Public Health; 2023 Jan; 16(1):42-54. PubMed ID: 36470006
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
[TBL] [Abstract][Full Text] [Related]
7. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
[TBL] [Abstract][Full Text] [Related]
8. Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2.
Bekheit MS; Panda SS; Girgis AS
Eur J Med Chem; 2023 Apr; 252():115292. PubMed ID: 36965227
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir.
Bai F; Beringheli T; Vitaletti V; Santoro A; Molà F; Copes A; Gemignani N; Pettenuzzo S; Castoldi R; Varisco B; Nardo R; Lundgren LB; Ligresti R; Sala M; Albertini L; Augello M; Biasioli L; Bono V; Rovito R; Bini T; Passarella S; Orfeo NV; Monforte AD; Marchetti G
Infect Dis Ther; 2024 Jun; ():. PubMed ID: 38829439
[TBL] [Abstract][Full Text] [Related]
10. The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells.
Saleh MAA; Hirasawa M; Sun M; Gülave B; Elassaiss-Schaap J; de Lange ECM
Eur J Pharm Sci; 2023 Feb; 181():106345. PubMed ID: 36462547
[TBL] [Abstract][Full Text] [Related]
11. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
[TBL] [Abstract][Full Text] [Related]
12. Neurological side effects and drug interactions of antiviral compounds against SARS-CoV-2.
Akhvlediani T; Bernard-Valnet R; Dias SP; Eikeland R; Pfausler B; Sellner J;
Eur J Neurol; 2023 Dec; 30(12):3904-3912. PubMed ID: 37526048
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Saraca LM; Capogrossi L; Pasticci MB; Francisci D
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515263
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
Tan B; Joyce R; Tan H; Hu Y; Wang J
Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
[TBL] [Abstract][Full Text] [Related]
15. Genetic Surveillance of SARS-CoV-2 M
Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Vangeel L; Chiu W; De Jonghe S; Maes P; Slechten B; Raymenants J; André E; Leyssen P; Neyts J; Jochmans D
Antiviral Res; 2022 Feb; 198():105252. PubMed ID: 35085683
[TBL] [Abstract][Full Text] [Related]
17. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
Sutanto ST; Sinto R; Pasaribu A; Shakinah S
Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of
Tong X; Keung W; Arnold LD; Stevens LJ; Pruijssers AJ; Kook S; Lopatin U; Denison M; Kwong AD
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0084023. PubMed ID: 37800975
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
Elife; 2021 Oct; 10():. PubMed ID: 34617885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
